| __timestamp | Geron Corporation | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8901000 | 14400000 |
| Thursday, January 1, 2015 | 9574000 | 33800000 |
| Friday, January 1, 2016 | 14695000 | 35900000 |
| Sunday, January 1, 2017 | 8437000 | 1254000 |
| Monday, January 1, 2018 | 12723000 | 4889000 |
| Tuesday, January 1, 2019 | 51272000 | 7400000 |
| Wednesday, January 1, 2020 | 50052000 | 10100000 |
| Friday, January 1, 2021 | 783000 | 14300000 |
| Saturday, January 1, 2022 | 868000 | 23200000 |
| Sunday, January 1, 2023 | 123740000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Data in motion
In the competitive landscape of biotechnology, cost efficiency is paramount. Neurocrine Biosciences, Inc. and Geron Corporation, two prominent players, showcase contrasting strategies in managing their cost of revenue from 2014 to 2023. Neurocrine Biosciences consistently maintained a lower cost of revenue, averaging around $18.5 million annually, with a notable dip in 2017 to just $1.3 million. This reflects a strategic focus on cost containment, possibly due to streamlined operations or strategic partnerships.
Conversely, Geron Corporation's cost of revenue fluctuated significantly, peaking in 2023 with a staggering $123.7 million, a 14-fold increase from its 2021 low. This volatility may indicate aggressive investment in research and development or scaling operations. Understanding these trends offers valuable insights into each company's operational priorities and financial health, crucial for investors and industry analysts alike.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Dr. Reddy's Laboratories Limited vs Geron Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Sarepta Therapeutics, Inc. and Geron Corporation
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Geron Corporation
Geron Corporation vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Geron Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored